Founder and chair, Hansoh Pharmaceutical Group
Appears in 1 story
Steering Hansoh's pivot from generics to innovative oncology
Patients with advanced esophageal squamous cell carcinoma who fail both chemotherapy and immunotherapy have almost no good options. On May 11, China's drug regulator granted breakthrough status to Hansoh Pharmaceutical's HS-20093, a targeted cancer drug built around a protein called B7-H3.
Updated May 11
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
